PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
June 16, 2016 updated by: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
The Multi-center,Open-label,Single Arm Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.
Study Overview
Study Type
Interventional
Enrollment (Actual)
410
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with age ≥ 18 years
- diagnosis of lymphoma(Hodgkin's lymphoma and non-Hodgkin's lymphoma) patients
- Karnofsky Performance Status Z70
- life expectancy of at least 8 months
- normal white blood cell count and platelet count
- Written informed consent are acquired
Exclusion Criteria:
- uncontrolled infection
- pregnancy
- Have accepted any other anti-tumor drug within 4 weeks before anticipated the study
- Other situations that investigators consider as contra-indication for this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PEG-rhG-CSF
patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The occurrence rate of adverse event
Time Frame: up to 30 days after the patient study completion
|
up to 30 days after the patient study completion
|
|
The severity of adverse event
Time Frame: up to 30 days after the patient study completion
|
up to 30 days after the patient study completion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
the occurrence rate of grade III/ IV neutropenia during chemotherapy cycles
Time Frame: through the study completion,an average of 5 months
|
through the study completion,an average of 5 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Actual)
February 1, 2016
Study Completion (Actual)
February 1, 2016
Study Registration Dates
First Submitted
June 13, 2016
First Submitted That Met QC Criteria
June 15, 2016
First Posted (Estimate)
June 17, 2016
Study Record Updates
Last Update Posted (Estimate)
June 20, 2016
Last Update Submitted That Met QC Criteria
June 16, 2016
Last Verified
June 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSPC-PGC-IV-02-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.